

CURRICULUM VITAE -- SASCHA DUBLIN

ADDRESS 1730 Minor Avenue, Suite 1600, Seattle, WA 98101-1448
phone (206) 287-2870; fax (206) 287-2871; dublin.s@ghc.org

CURRENT POSITION

Associate Scientific Investigator, Group Health Research Institute (formerly Center for Health Studies),
Seattle, WA, 4/2013-present
Assistant Scientific Investigator, Group Health Research Institute (formerly Center for Health Studies),
Seattle, WA, 9/2007-4/2013
Affiliate Assistant Professor, Epidemiology Department, School of Public Health, University of
Washington, Seattle, WA, 1/2008-7/2014
Affiliate Associate Professor, Epidemiology Department, School of Public Health, University of
Washington, Seattle, WA, 7/2014-present

EDUCATION AND TRAINING

A.B. Renaissance Studies, *magna cum laude*, Brown University, Providence, RI, 1992
M.D./Ph.D (in Epidemiology), University of Washington, Seattle, WA; Ph.D. 12/99, M.D 6/01
Residency, Internal Medicine, Oregon Health & Science University, Portland, OR (completed 6/04)
Fellow, Health Services Research & Development, VA Puget Sound, Seattle, WA (7/04-8/07)

HONORS AND AWARDS

1990 Kenneth Grief Prize for best essay on Shakespeare, Brown University, Providence, RI
1991 Phi Beta Kappa
1992 Thomas & Lydia Carpenter Premium, Brown University, Providence, RI
1994 Birch Award, American Medical Women's Assoc. - best research paper by a medical student
1997 Association of Women in Science Educational Foundation Citation of Merit
1997 Bertakis Award for Outstanding Oral Presentation, Western Student Medical Research Forum
1997 Student Workshop, Society for Epidemiologic Research, Edmonton, Canada
1997 New Investigators' Workshop, American Society for Preventive Oncology, New Orleans, LA
1997 Magnuson Scholar, University of Washington, Seattle, WA
1998 Achievement Rewards for College Scientists fellowship
1999 Lilienfeld Prize, Society for Epidemiologic Research - best research paper by graduate student
1999 Outstanding Student Award, Epidemiology Dept., University of Washington, Seattle, WA
2003 Alpha Omega Alpha medical honors society
2004 Humanitarianism award, Internal Medicine residency, OHSU
2004 Outstanding Teaching award, Internal Medicine residency, OHSU
2006 Summer Institute on Aging Research, National Institute on Aging, Wye River, MD
2007 Paul Beeson Career Development Award in Aging, National Institute on Aging
2008 Outstanding Reviewer, *Annals of Internal Medicine* (also named in 2009-2012)
2009 Distinguished Reviewer, *Journal of General Internal Medicine*
2009 Selected for Young Investigators plenary session, HMO Research Network Annual Meeting
2010 Merck/American Geriatrics Society New Investigator Award
2010 Outstanding Poster Award, American Geriatrics Society Annual Meeting
2011 Early Career Investigator Award, HMO Research Network Annual Meeting
2011 Emerging Clinical Leaders program, Group Health, Seattle, WA (ongoing program)
2012 Honorable Mention, Ronald D. Mann Best Paper Award, *Pharmacoepidemiology and Drug*

- Safety* (co-author)
- 2013 Outstanding Reviewer, *Pharmacoepidemiology and Drug Safety* (also named in 2010 and 2011)
- 2014 Invited faculty, Society for Epidemiologic Research Student Workshop, Seattle, WA, June 2014
- 2014 Best paper award (co-author), Epidemiology Section, American Geriatrics Society Annual Scientific Meeting

GRANTS AND CONTRACTS

ACTIVE

R01 HD071986 (PIs: Dublin and Getahun) 9/1/2013-5/31/2017

National Institute of Child Health and Human Development

Title: Elective Induction of Labor and Pregnancy Outcomes

Major Goals: 1) To examine maternal and infant outcomes associated with elective induction of labor compared to expectant management at 38, 39 and 40 weeks of gestation; and 2) to examine how risks vary according to maternal race/ethnicity, parity, and obesity status.

Role: Co-Principal Investigator

HHSF223200910006I (PI: Platt) 12/18/2013-5/17/2015

Food and Drug Administration

Title: Efforts to Develop the Sentinel Initiative: A Protocol-based Assessment of Selected Medications and Death

Major Goals: To develop and implement protocols to assess the associations of antibiotics and antidepressants with sudden cardiac death, including assessing the feasibility of linking the Mini-Sentinel Distributed Database with the National Death Index and establishing a process for this linkage.

Role: Co-Investigator

HHSF223200910006I (Platt) 1/1/2014-3/31/2015

Food and Drug Administration

Title: Efforts to Develop the Sentinel Initiative: Analytical Methods to Access the Robustness of Drug Safety Monitoring

Major Goals: To identify and implement sensitivity analyses that can be carried out within the Mini-Sentinel context to examine the potential impact on results of biases such as residual confounding, exposure, and outcome and covariate misclassification. The workgroup will utilize Mini-Sentinel data resources in conjunction with existing modules for expedited drug safety monitoring in the Mini-Sentinel Distributed Database (MSDD). The workgroup will also produce a user manual for the software programs developed during this activity.

Role: Workgroup member

HHSF223200510012C-COA7 (PI: Platt) 9/1/2013-8/31/2014

Food and Drug Administration

Title: Medication Exposure in Pregnancy Risk Evaluation Program Continuation

Major Goals: To maintain all data, data linkages, standardized datasets, and organizational structure created in the Medication Exposure in Pregnancy Risk Evaluation Program pilot program.

Role: Site Principal Investigator

2U01AG006781-22A1 (PI: Larson) 9/15/2009-8/31/2014

National Institute on Aging

Title: Alzheimer's Disease Patient Registry

Major Goals: To determine cardiovascular and pharmacologic risk factors for Alzheimer disease in a community-based epidemiological study begun over 20 years ago. We will investigate mid- and late-life diseases that target microvessels (diabetes and renal disease) as well as atrial fibrillation (Aim 1) and late-life measures of physical performance (Aim 2) as determinants of such injury.

Role: Co-Investigator (leading atrial fibrillation aim)

None (PI: Dublin)

1/1/2011-12/31/2014

Branta Foundation

Title: Pneumonia Risk Project

Major Goals: 1) To examine pneumonia risk in relation to use of angiotensin-converting enzyme inhibitors; 2) to compare different methods for studying medications and pneumonia risk, identifying and disseminating "best practices"; and 3) to develop a risk score for pneumonia based on simple and easily obtained measures.

Role: Principal Investigator

R03 AG042930 (PI: Dublin)

8/1/2012-7/31/2014

National Institute on Aging

Title: Opioids and the Aging Brain: Dementia, Cognitive Decline and Neuropathology

Major Goals: To examine whether long-term use of prescription opioids is associated with a) higher incidence of all-cause dementia or Alzheimer's disease; b) more rapid decline in global cognitive functioning, and c) higher burden of Alzheimer's disease neuropathology.

Role: Principal Investigator

None (PI: Dublin)

8/1/2012-7/31/2014

Branta Foundation

Title: Medications and Dementia Risk in Older Adults

Major Goals: To study the association between 3 medication classes - opioid pain medications, benzodiazepines, and general anesthesia - and brain outcomes in older adults, including dementia, global cognitive trajectory, and neuropathology. The opioid analyses will 1) compare the impact of long versus short acting medications and 2) assess whether opioid effects differ in subgroups including by age, gender, and baseline cognitive function.

Role: Principal Investigator

COMPLETED

HHSF223200910006I (PI: Platt)

5/8/2012-12/31/2013

Food and Drug Administration

Title: Efforts to Develop the Sentinel Initiative: Birth Certificate Data Matching for the Post-Licensure Rapid Immunization Safety Monitoring (PRISM) Program

Major Goals: To expand the data available for post-marketing vaccine safety surveillance by investigating and supporting matching of health plan data to state birth certificate and fetal death certificate data for Mini-Sentinel Data Partners.

Role: Co-Investigator

HHSF223200910006I (PI: Platt)

9/1/2012-10/31/2013

Food and Drug Administration

Title: Efforts to Develop the Sentinel Initiative: Using Supplemental Information for Improved Confounder Adjustment

Major Goals: 1) To develop a 2-phase sampling design strategy for supplemental data collection (e.g. medical record review) to refine a signal detected in automated data; 2) To develop a framework to

determine which confounders should be collected; and 3) To develop an alternative strategy through which supplemental information could be collected on an ongoing basis, before a signal is detected.

Role: Workgroup Lead

HHSF22301008T (PI: Platt)

9/12/2012-9/11/2013

Food and Drug Administration

Title: Feasibility Assessment for Retrospective Cohort Study of Risk of Hip Fractures Associated with High Dose, Long Term Proton Pump Inhibitor (PPI) Use or H2 Receptor Antagonists (H2RA) and Cytochrome P450 Pharmacogenomics

Major Goals: 1) To create and describe a cohort of new users of prescription PPI or H2RA, including a nonuser comparison group, including evidence of ability to link patient records to biospecimens; and 2) to develop innovative strategies to address confounding by indication and analyze pharmacogenetic influences of CYP2C19 inhibition.

Role: Co-Investigator

K23 AG028954 (PI: Dublin)

9/15/2007-8/31/2013

National Institute on Aging

Title: Pharmacoepidemiology in the elderly: medications, pneumonia risk and confounding. Paul Beeson Career Development Award in Aging.

Major Goals: To develop a career as an independent physician-investigator studying medication safety in older adults; to provide new knowledge about medications and risk of pneumonia in older adults; and to contribute to improved research methods in studies of medication safety in older adults.

Role: Principal Investigator

HHSF223200510012C-COA7 (PI: Platt)

9/14/2011-8/31/2013

Food and Drug Administration

Title: Systemic Sulfonamide Use During Pregnancy and the Risk of Selected Congenital Abnormalities in the Offspring

Major Goals: 1) To measure the association between exposure to sulfonamides during pregnancy and congenital abnormalities in the offspring. 2) To maintain all data, data linkages, standardized datasets, and organizational structure created in the Medication Exposure in Pregnancy Risk Evaluation Program pilot program.

Role: Site Principal Investigator

None (PI: Dublin)

1/1/2010-12/31/2012

Group Health Research Institute Development Fund

Title: Natural Language Processing to Identify Pneumonia from Radiology Reports

Major Goal: To validate Natural Language Processing tools to identify pneumonia cases from electronic radiology text reports and to assess these tools' transferability to other health care systems.

Role: Principal Investigator

HHSF223200510012C-COA7 (PI: Platt)

10/1/2010-9/30/2011

Food and Drug Administration

HMORN CERT Epidemiological Studies of the Adverse Effects of Marketed Drugs: Prescribing in Pregnancy

Major Goals: This project builds on previous work creating a multisite data repository for studies of birth outcomes. The specific objectives are: 1) to evaluate gestational age assumptions based upon administrative health plan data compared to birth certificate data, and 2) to describe the prevalence and patterns of use of antidiabetic medications during pregnancy.

Role: Site Principal Investigator

HHSF223200910006I (Platt) 4/1/2010-7/31/2011
Food and Drug Administration
Title: Efforts to Develop the Sentinel Initiative: Review of the Evidence for Selected Health Outcomes of Interest (HOIs): Atrial Fibrillation
Major Goals: To review the literature to identify algorithms that have been examined to identify atrial fibrillation using electronic health data, summarize the test characteristics of those algorithms, and identify areas for future research.
Role: Principal Investigator

P30 AG0345592 (PI: Teri) 9/30/2009-8/31/2011
National Institutes of Health
Title: Cognitive Function and Breast Cancer Care – Roybal Center
Major Goals: To investigate how often cognitive and functional status are assessed prior to treatment for breast cancer and to determine how these characteristics influence treatment decisions.
Role: Co-Investigator on this Roybal Center pilot project

HHSF223200510012C (Platt) 10/4/2010-7/31/2011
Food and Drug Administration
Title: Center for Drug Evaluation and Research Antiepileptic Study
Major Goals: This project will build on work started during Year 2 of CERT III where the process for multisite active surveillance for medication safety was developed and tested. We will develop additional methods to understand and overcome potential biases that arise during active drug safety surveillance. This work will focus on the brand-to-generic transition of several antiepileptic medications.
Role: Site Principal Investigator

U18 HS016955 (PI: Platt) 9/1/2007-8/31/2011
Agency for Healthcare Research and Quality
Title: HMO Research Network Center for Education and Research on Therapeutics III: Infrastructure
Major Goals: To continue studies on drug safety and pharmacovigilance in a population-based setting. The Year 4 pilot project led by Dr. Dublin has the following aims: 1) to describe labor induction trends across 10 health plans from 2001-2007, including induction without a documented indication; 2) to describe characteristics of women undergoing elective induction compared to medically indicated induction or no induction; and 3) to validate the algorithm for elective induction through medical record review.
Role: Lead Investigator for Year 4 project; Site Principal Investigator in all years

HHSF223200510012C-COA7 (Platt) 8/18/2008-9/22/2010
Food and Drug Administration
Title: HMORN CERT Epidemiological Studies of the Adverse Effects of Marketed Drugs: Prescribing in Pregnancy
Major Goals: This multisite collaborative project will develop infrastructure to enable the ongoing study of medication use and outcomes in pregnancy. Specific components include: 1) maternal-infant record linkage; 2) linkage to infants' birth certificate data; 3) validation of data elements through medical chart abstractions; and 4) annual update of the datasets.
Role: Site Principal Investigator, Group Health

5 U18 HS016955 (PI: Platt) 9/1/2008-8/31/2010
Agency for Healthcare Research and Quality
Title: HMO Research Network CERT III – Adverse Drug Reactions

Major Goals: Aim 1) to pilot test prospective surveillance, using sequential testing methodologies, for identifying serious adverse drug reactions (ADRs) to newly marketed drugs. This project will examine safety of new generic antiepileptic drugs compared to the equivalent branded medications. Aim 2) To develop a new mixed structure model data mining method.

Role: Site Principal Investigator, Group Health

HHSF223200510010C (PI: Platt)

7/1/2008-6/30/2009

Food and Drug Administration

Title: HMORN CERT Epidemiological Studies of the Adverse Effects of Marketed Drugs: ADHD and Cardiovascular Outcomes: Medical Record Review

Major Goals: To validate data elements from the ADHD Phase I study by reviewing charts of patients suffering ischemic or hemorrhagic stroke.

Role: Site Principal Investigator, Group Health

HHS290200500331-TO4-WA1 (PI: Platt)

9/1/2007-2/28/2009

Agency for Healthcare Research and Quality

Title: A Multicenter, Observational Cohort Study To Assess the Cardiovascular Risks of Medications Prescribed for Attention Deficit Hyperactivity Disorder

Major Goals: To examine the risks of serious cardiovascular events including stroke, sudden cardiac death, and myocardial infarction in children and adults receiving medications for ADHD.

Role: Site Principal Investigator, Group Health

Ovarian Cancer and Prescription Drug Use. University of WA Royalty Research Fund. Project director (dissertation project; P.I. Dr. Noel Weiss). August 1997-July 1998.

Johnson & Johnson/Woodrow Wilson Foundation Dissertation Grant in Women's Health, 1997.

PEER-REVIEWED ARTICLES

1. **Dublin S**, Rosenberg P, Goedert JJ. Patterns and predictors of high-risk sexual behavior in female partners of HIV-infected men with hemophilia. *AIDS* 1992 May;6(5):475-82.
2. Goedert JJ, **Dublin S**. Perinatal transmission of HIV type 1: associations with maternal anti-HIV serological reactivity. *AIDS Res and Hum Retroviruses* 1994 Sep;10(9):1125-34.
3. **Dublin S**, Riccardi V, Stephens K. Methods for rapid detection of a recurrent nonsense mutation and documentation of phenotypic features in neurofibromatosis type 1 patients. *Hum Mutat* 1995;5(1):81-5.
4. Weiss NS, **Dublin S**. Accounting for time-dependent covariates whose levels are influenced by exposure status. *Epidemiology* 1998 Jul;9(4):436-40.
5. **Dublin S**, Lydon-Rochelle M, Kaplan R, Watts DH, Critchlow CW. Maternal and neonatal outcomes after induction of labor without an identified indication. *Am J Obstet Gynecol* 2000 Oct;183(4):986-94.
6. **Dublin S**, Rossing MA, Heckbert SR, Goff BA, Weiss NS. Risk of ovarian cancer in relation to use of antidepressants, benzodiazepines, and other centrally-acting medications. *Cancer Causes Control* 2002 Feb;13(1):35-45.
7. Velicer CM, **Dublin S**, White E. Cimetidine use and the risk of prostate cancer: results from the VITAL cohort study. *Ann Epidemiol* 2006 Dec;16(12):895-900. Epub 2006 Jul 12.
8. Velicer CM, **Dublin S**, White E. Diabetes and the risk of prostate cancer: the role of diabetes treatment and complications. *Prostate Cancer Prostatic Dis* 2007;10(1):46-51. Epub 2006 Oct 10.

9. **Dublin S**, French B, Glazer NL, Wiggins KL, Lumley T, Psaty BM, Smith NL, Heckbert SR. Risk of new-onset atrial fibrillation in relation to body mass index. *Arch Intern Med* 2006 Nov 27;166(21):2322-8.
10. Glazer NL, **Dublin S**, Smith NL, French B, Jackson LA, Hrachovec JB, Siscovick DS, Psaty BM, Heckbert SR. Newly detected atrial fibrillation and compliance with antithrombotic guidelines. *Arch Intern Med* 2007 Feb 12;167(3):246-52.
11. Lovasi GS, Lemaitre RN, Siscovick DS, **Dublin S**, Bis JC, Lumley T, Heckbert SR, Smith NL, Psaty BM. Amount of leisure-time physical activity and risk of nonfatal myocardial infarction. *Ann Epidemiol* 2007 Jun;17(6):410-6. Epub 2007 Feb 22.
12. McFarland LV, **Dublin S**. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. *World J Gastroenterol* 2008 May 7;14(17):2650-61. PMC2709042.
13. Thomas MC, **Dublin S**, Kaplan RC, Glazer NL, Lumley T, Longstreth WT Jr, Smith NL, Psaty BM, Siscovick DS, Heckbert SR. Blood pressure control and risk of incident atrial fibrillation. *Am J Hypertens* 2008 Oct;21(10):1111-6. Epub 2008 Aug 28. PMC2577029.
14. Heckbert SR, Wiggins KL, Glazer NL, **Dublin S**, Psaty BM, Smith NL, Longstreth Jr WT, Lumley T. Antihypertensive treatment with ACE inhibitors or beta-blockers and risk of incident atrial fibrillation in a general hypertensive population. *Am J Hypertens* 2009 May;22(5):538-44. Epub 2009 Mar 5. PMC2672972.
15. Breitner JCS, Haneuse SJPA, Walker R, **Dublin S**, Crane PK, Gray SL, Larson EB. Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. *Neurology* 2009 Jun 2;72(22):1899–1905. Epub 2009 Apr 22. PMC2690966.
16. **Dublin S**, Jackson MJ, Nelson JC, Weiss NS, Larson EB, Jackson LA. Statin use and risk of community acquired pneumonia in older people: population based case control study. *BMJ* 2009 Jun 16;338:b2137. doi: 10.1136/bmj.b2137. PMC2697311.
17. Thacker EL, Wiggins KL, Rice KM, Longstreth WT, Bis JC, **Dublin S**, Smith NL, Heckbert SR, Psaty BM. Short term and long term risk of incident ischemic stroke after transient ischemic attack. *Stroke* 2010 Feb;41(2):239-43. Epub 2009 Dec 3. PMC2818812.
18. **Dublin S**, Glazer NL, Smith NL, Psaty BM, Lumley T, Wiggins KL, Page RL, Heckbert SR. Diabetes mellitus, glycemic control, and risk of atrial fibrillation. *J Gen Intern Med* 2010 Aug;25(8):853-8. Epub 2010 Apr 20. PMC2896589.
19. **Dublin S**, Walker RL, Jackson ML, Nelson JC, Weiss NS, Jackson LA. Use of proton pump inhibitors and histamine-type 2 receptor blockers and risk of pneumonia in older adults: a population-based case-control study. *Pharmacoepidemiol Drug Saf* 2010 Aug;19(8):792-802. PMC2938739.
20. Davis RL, Eastman D, McPhillips H, Raebel MA, Andrade SE, Smith D, Yood MU, **Dublin S**, Platt R. Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy. *Pharmacoepidemiol Drug Saf* 2011 Feb;20(2):138-45. doi: 10.1002/pds.2068. Epub 2010 Nov 15. PMC3232183.
21. Gray SL, Walker R, **Dublin S**, Haneuse S, Crane PK, Breitner JCS, Bowen J, McCormick W, Larson EB. Histamine-2 receptor antagonist use and incident dementia in an older cohort. *J Amer Geriatr Soc* 2011 Feb;59(2):251-7. doi: 10.1111/j.1532-5415.2010.03275.x. PMC3115775.
22. **Dublin S**, Anderson ML, Heckbert SR, Haneuse SJ, Crane PK, Breitner JCS, McCormick W, Bowen JD, Teri L, McCurry SM, Larson EB. Atrial fibrillation and risk of dementia: a prospective cohort study. *J Amer Geriatr Soc* 2011 Aug;59(8):1369-75. doi: 10.1111/j.1532-5415.2011.03508.x. Epub 2011 Aug 1. PMC3289545.
23. **Dublin S**, Walker RL, Jackson ML, Nelson JC, Weiss NS, Von Korff M, Jackson LA. Use of opioids or benzodiazepines and risk of pneumonia in older adults: a population-based case-control study. *J Am Geriatr Soc* 2011 Oct;59(10):1899-907. doi: 10.1111/j.1532-5415.2011.03586.x. Epub 2011 Sept 13. PMC3223721.
24. Andrade SE, Davis RL, Cheetham TC, Cooper WO, Li DK, Amini T, Beaton SJ, **Dublin S**, Hammad TA, Pawloski PA, Raebel MA, Smith DH, Staffa JA, Toh S, Dashevski I, Haffnerreffer K, Lane K,

- Platt R, Scott PE. Medication exposure in pregnancy risk evaluation program. *Matern Child Health J* 2011 Oct;16(7):1349-54. PMC3361624.
25. Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, Cheetham TC, Quinn VP, **Dublin S**, Boudreau DM, Andrade SE, Pawloski PA, Raebel MA, Smith DH, Achacoso N, Uratsu C, Go AS, Sidney S, Nguyen-Huynh N, Ray WA, Selby JV. ADHD Medications and Risk of Serious Cardiovascular Events In Young and Middle-Aged Adults. *JAMA* 2011 Dec 28;306(24):2673-83. Epub 2011 Dec 12. PMC3350308.
 26. *Jensen PN, Johnson K, Floyd J, Heckbert SR, Carnahan R, **Dublin S**. A systematic review of validated methods for identifying atrial fibrillation using administrative data. *Pharmacoepidemiol Drug Saf* 2012 Jan;21(S1):141-47. doi: 10.1002/pds.2317. PMC3674852.
 27. Hansen C, Joski P, Freiman HC, Andrade SE, Toh S, **Dublin S**, Cheetham TC, Cooper WO, Pawloski PA, Li D-K, Beaton SJ, Scott PE, Hammad T, Davis RL. Medication in Pregnancy Risk Evaluation Program: the prevalence of asthma medication use during pregnancy. *Matern Child Health J* 2012 Oct 30. [Epub ahead of print]
 28. **Dublin S**, Walker RL, Jackson ML, Nelson JC, Weiss NS, Jackson LA. Angiotensin-converting enzyme inhibitor use and pneumonia risk in community-dwelling older adults: results from a population-based case-control study. *Pharmacoepidemiol Drug Saf* 2012 Nov;21(11):1173-1182. doi: 10.1002/pds.3340. PMC3740964.
 29. Bobo WV, Davis RL, Toh SD, Li D-K, Andrade SE, Cheetham TC, Pawloski PA, **Dublin S**, Pinheiro S, Hammad T, Scott PE, Epstein RA, Arbogast PG, Morrow JA, Dudley JA, Lawrence JM, Avalos LA, Cooper WO. Trends in the use of antiepileptic drugs among pregnant women in the US, 2001-2007: a Medication Exposure in Pregnancy Risk Evaluation Program study. *Paediatr Perinat Epidemiol.* 2012 Nov;26(6):578-588. doi: 10.1111/ppe.12004. PMC3481178.
 30. Andrade SE, Scott PE, Davis RL, Li D-K, Getahun DT, Cheetham TC, Raebel MA, Toh S, **Dublin S**, Pawloski PA, Hammad TA, Beaton SJ, Smith DH, Dashevsky I, Haffner K, Cooper WO. Validity of health plan and birth certificate data for pregnancy research. *Pharmacoepidemiol Drug Saf* 2013 Jan;22(1):7-15. doi: 10.1002/pds.3319. PMC3492503.
 31. Thacker EL, McKnight B, Psaty BM, Longstreth WT, **Dublin S**, Jensen PN, Newton KM, Smith NL, Siscovick DS, Heckbert SR. Association of body mass index, diabetes, hypertension, and blood pressure levels with risk of permanent atrial fibrillation. *J Gen Intern Med* 2013 Feb;28(2):247-253. doi: 10.1007/s11606-012-2220-4. PMC3614136.
 32. Lawrence JM, Andrade SE, Avalos LA, Beaton SJ, Chiu VY, Davis RL, **Dublin S**, Pawloski PA, Raebel MA, Smith DH, Toh S, Wang JQ, Kaplan S, Amini T, Hampp C, Hammad TA, Scott PE, Cheetham TC; for the Medication Exposure in Pregnancy Risk Evaluation Program (MEPREP) Study Group. Prevalence, trends and patterns of use of antidiabetic medications among pregnant women, 2001-2007. *Obstet Gynecol* 2013; 121:106-114. PMC3811068
 33. Jensen PN, Thacker EL, **Dublin S**, Psaty BM, Heckbert SR. Racial differences in the incidence of and risk factors for atrial fibrillation in older adults: the Cardiovascular Health Study. *J Amer Geriatr Soc* 2013 Feb;61(2):276-280. doi: 10.1111/jgs.12085. PMID:PMC3878638.
 34. Li Q, Andrade SE, Cooper WO, Davis RL, **Dublin S**, Hammad TA, Pawloski PA, Pinheiro SP, Raebel MA, Scott PE, Smith DH, Dashevsky I, Haffner K, Johnson KE, Toh S. Validation of an algorithm to estimate gestational age in electronic health plan databases. *Pharmacoepidemiol Drug Saf.* 2013 May; 22(5)524-532. doi: 10.1002/pds.3407. Epub 2013 Jan 21. PMC3644383.
 35. Avery TR, Kulldorff M, Vilk Y, Lingling L, Cheetham TC, **Dublin S**, Davis RL, Liu L, Herrinton L, Brown JS. Near real-time adverse drug reaction surveillance within population-based health networks: methodology considerations for data accrual. *Pharmacoepidemiol Drug Saf* 2013;22(5):488-95. doi: 10.1002/pds.3412. Epub 2013 Feb 12. PMC3644310.
 36. Toh S, Li Q, Cheetham TC, Cooper WO, Davis RL, **Dublin S**, Hammad TA, Li D-K, Pawloski PA, Pinheiro SP, Raebel MA, Smith DH, Bobo WV, Lawrence JM, Dashevsky I, Haffner K, Avalos LA, Andrade SE. Prevalence and trends in the use of antipsychotic drugs during pregnancy in the

- US: a population-based study of 585,615 deliveries. *Arch Women's Mental Health* 2013;16(2):149-57. doi: 10.1007/s00737-013-0330-6. Epub 2013 Feb 7. PMC3715880.
37. Avalos LA, Chen HY, Yang C, Andrade SE, Cooper WO, Cheetham TC, Davis RL, **Dublin S**, Hammad TA, Kaplan S, Pawloski PA, Raebel MA, Scott PE, Smith DH, Toh S, Li D-K. The prevalence and trends of antiviral medication use during pregnancy in the US: A population-based study of 664,297 deliveries in 2001-2007. *Maternal and Child Health Journal*. 2013 Feb 19. [Epub ahead of print]. PMC3776000.
 38. **Dublin S**, Baldwin E, Walker RL, Christensen LM, Haug PJ, Jackson ML, Nelson JC, Ferraro J, Carrell D, Chapman WW. Natural Language Processing to identify pneumonia from radiology reports. *Pharmacoepidemiol Drug Saf*, 2013 Aug;22(8):834-841. doi: 10.1002/pds.3418. Epub 2013 Apr 1. PMC3811072.
 39. Johnson KE, Beaton SJ, Andrade SE, Cheetham TC, Scott PE, Hammad TA, Dashevsky I, Cooper WO, Davis RL, Pawloski PA, Raebel MA, Smith DH, Toh S, Li D-K, Haffenreffer K, **Dublin S**. Methods of linking mothers and infants using health plan data for studies of pregnancy outcomes. *Pharmacoepidemiol Drug Saf* 2013 Jul;22(7):776-786.. doi: 10.1002/pds.3443. Epub 2013 Apr 18. PMC3707923.
 40. Thacker EL, McKnight B, Psaty BM, Longstreth WT, Sitlani CM, **Dublin S**, Arnold AM, Fitzpatrick AL, Gottesman R, Heckbert SR. Atrial fibrillation and cognitive decline: a longitudinal cohort study. *Neurology*, 2013 Jul 9;81(2):119-125. Epub 2013 Jun 5. PMC3770176.
 41. **Dublin S**, Anderson ML, Heckbert SR, Hubbard RA, Sonnen JA, Crane PK, Montine TJ, Larson EB. Neuropathologic changes associated with atrial fibrillation in a population-based autopsy cohort. *J Gerontol A Biol Sci Med Sci*, 2014 May; 69(5)609-15. doi: 10.1093/gerona/glt141. Epub 2013 Sep 28. PMID:PMC3991149
 42. Darney BG, Snowden JM, Cheng YW, Jacob L, Nicholson JM, Kaimal A, **Dublin S**, Getahun D, Caughey AB. Elective induction of labor at term compared to expectant management: Maternal and neonatal outcomes. *Obstet Gynecol* 2013;122(4):761-9. doi: 10.1097/AOG.0b013e3182a6a4d0. PMC3905733.
 43. **Dublin S**, Johnson KE, Walker RL, Getahun D, Andrade SE, Avalos LA, Beaton SJ, Davis RL, Herrinton LJ, Pawloski PA, Raebel MA, Smith DH, Toh S, Caughey AB. Trends in elective labor induction at 6 US health plans, 2001-2007. *J Women's Health*, in press.

*First author is a student whom I supervised for this work.

TECHNICAL REPORTS

*Jensen PN, **Dublin S**, Johnson K, Floyd J, Heckbert SR. Mini-Sentinel Systematic Evaluation of Health Outcome of Interest Definitions for Studies Using Administrative Data: Atrial Fibrillation Report. Posted June 30, 2011. URL: http://www.mini-sentinel.org/work_products/HealthOutcomes/Mini-Sentinel-HOI-Evidence-Review-Atrial-Fibrillation-Report.pdf

Dublin S, Walker R, Rutter C, Nelson J, Fireman B, Graham D, Psaty B, Setoguchi S, Shaoibi A. Mini-Sentinel Methods: Collecting Supplemental Information via Two-phase Study Designs to Investigate Signals Arising from Medication Safety Surveillance Activities. Posted January 14, 2014. URL: http://www.mini-sentinel.org/work_products/Statistical-Methods/Mini-Sentinel-Methods-Supplemental-Information-Two-Phase-Study-Designs.pdf

SUBMITTED MANUSCRIPTS

Dublin S, Walker RL, Gray SL, Hubbard RA, Anderson ML, Yu O, Crane PK, Larson EB. Prescription opioids and risk of dementia or cognitive decline: a prospective cohort study.

Baldwin E, Johnson K, Berthoud H, **Dublin S**. Linking mothers and infants within electronic health records: a comparison of deterministic and probabilistic algorithms. *Pharmacoepi and Drug Safety*, revise and resubmit.

Gray SL, Anderson ML, **Dublin S**, Hanlon JT, Hubbard R, Walker R, Yu, O, Crane P, Larson EB. Cumulative anticholinergic medication use and incident dementia.

SELECTED PRESENTATIONS, POSTERS AND ABSTRACTS

Gray S, Anderson ML, **Dublin S**, Hanlon J, Yu O, Walker R, Hubbard R, Crane P, Larson E. Anticholinergic medication use and incident dementia. Oral presentation and winner of Best Paper Award, Epidemiology Section, American Geriatrics Society Annual Scientific Meeting, Orlando, Florida, May 2014. *J Am Geriatr Soc* 2014; 62(Supp. 1): S11.

Dublin S. Benzodiazepine use and risk of dementia (oral presentation). 20th Annual HMO Research Network Conference, Phoenix, AZ, April 3, 2014.

Dublin S, Walker RL, Gray SL, Hubbard RA, Anderson ML, Yu O, Crane PK, Larson EB. Prescription opioid use and risk of dementia or cognitive decline (poster; selected for Best Poster competition.) 20th Annual HMO Research Network Conference, Phoenix, AZ, April 1, 2014.

Dublin S, Walker RL, Gray SL, Hubbard R, Anderson ML, Yu O, Crane PK, Larson EB. Use of opioids and risk of dementia in older adults (oral presentation). 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Montreal, Canada, August 26, 2013. Abstract: *Pharmacoepidemiology and Drug Safety* 2013; 22(Suppl 1): 8. Epublished 7 Oct 2013. DOI: 10.1002/pds.3512.

Dublin S, Jackson ML, Marsh T, Setoguchi-Iwata S, Jonsson Funk M, Brookhart MA. New approaches to account for selection bias and confounding by frail health status (accepted symposium; I was the organizer and moderator). 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Montreal, Canada, August 27, 2013.

Dublin S, Solti I, Matheny ME, Kors JA, Carrell D. Unlocking the secrets of free text through natural language processing: an introduction for pharmacoepidemiologists (accepted symposium; I was the organizer and moderator). 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Montreal, Canada, August 28, 2013.

Dublin S, Johnson K, Beaton SJ, Cheetham TC, Scott PE, Toh SD, Cooper WO, Davis RL, Li D-K, Pawloski PA, Raebel MA, Smith DH, Hammad TA, Andrade SE. Methods for linking mothers and infants within health plans for medication safety research (oral presentation). International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Barcelona, Spain, August 26, 2012.

Dublin S, Johnson K, Walker RL, Getahun D, Andrade SE, Avalos LA, Beaton SJ, Davis RL, Herrinton L, Pawloski PA, Raebel MA, Smith DH, Toh D, Caughey AB. Trends in elective labor induction at 7 US health plans, 2001-2007 (poster). HMO Research Network Conference, Seattle, WA, May 1, 2012.

Dublin S, Walker RL, Jackson ML, Nelson JC, Weiss NS, Jackson LA. Use of angiotensin-converting enzyme inhibitors is not associated with decreased pneumonia risk (poster). International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Chicago, IL, August 14-17, 2011.

Dublin S, Walker RL, Jackson ML, Nelson JC, Weiss NS, Jackson LA. Discrepant results in pneumonia studies using solely administrative data compared to medical record review (oral presentation). International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Chicago, IL, August 15, 2011.

Brown JS, Petronis K, Bate A, Zhang F, Dashevsky I, Kulldorf M, Avery TR, Davis RL, Andrade SE, **Dublin S**, Boudreau DM, Herrinton L, Pawloski P, Raebel MA, Roblin D, Smith D, Platt R, Reynolds R. Comparing two methods for detecting adverse event signals in observational data: empirical Bayes gamma Poisson shrinker vs. tree-based scan statistic (oral presentation). International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Chicago, IL, August 14-17, 2011.

Dublin S, Baldwin E, Walker R, Haug P, Carrell D, Chapman W. Accuracy of Natural Language Processing To Identify Pneumonia From Electronic Radiology Reports (oral presentation, plenary session). 16th Annual HMO Research Network Conference, Boston MA, March 24, 2011. Received 2011 Early Career Investigator Award.

Dublin S, Avery T, Cheetham C, Davis R, Kulldorff M, Lin L, Liu L, Brown J. Feasibility Of Prospective Surveillance For Adverse Drug Events – Lessons Learned From A 12-Month Pilot Study (poster). 16th Annual HMO Research Network Conference, Boston MA, March 24, 2011.

Thacker EL, McKnight B, Psaty BM, Longstreth WT, **Dublin S**, Jensen PN, Newton KM, Smith NL, Siscovick DS, Heckbert SR. Associations of Demographic and Medical History Factors with Recurrence of Atrial Fibrillation and Progression to Permanent Atrial Fibrillation. Poster presentation at the American Heart Association Cardiovascular Epidemiology and Prevention Conference, March 2011.

Kay N, Lauper J, Sabourin K, **Dublin S**. Lower Risk of Adverse Delivery Outcomes with Non-indicated Induction of Labor. Joint Conference on Health: Innovation and Collaboration in Times of Change. Yakima, WA, October 11-12, 2010.

Avery TR, Vilck Y, Kulldorff M, Li L, Cheetham TC, **Dublin S**, Hsu J, Davis RL, Liu L, Platt R, Brown JS. Prospective, active surveillance for medication safety in population-based health networks: a pilot study (poster). International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Brighton, England, August 19-22, 2010.

Dublin S, Anderson ML, Heckbert SR, Haneuse SJ, Crane PK, Breitner JCS, McCormick W, Bowen JD, Teri L, McCurry SM, Larson EB. Atrial fibrillation and risk of incident dementia or Alzheimer's disease (poster). American Geriatrics Society Annual Scientific Meeting, Orlando, FL, May 12-15, 2010. *Journal of the American Geriatrics Society* 2010; 58:S122 (Abstract B135). Selected for Presidential Poster Session; received Outstanding Poster Award.

Moore K, Andrade S, Cassidy-Bushrow A, **Dublin S**, Greenlee R, Nakasato C, Platt R, Raebel M, Rolnick C, Smith D, Brown J. Variation in ICD-9 diagnosis coding within and across health

systems (poster). International Society for Pharmacoeconomics and Outcomes Research 14th Annual International Meeting, Orlando, FL, May 16-20, 2009.

Li T, **Dublin S**, Gray SL, Nelson JC, Weiss NS, Larson EB. Factors associated with suboptimal benzodiazepine use in an older US cohort, 2004-2006 (poster). American Geriatrics Society Annual Scientific Meeting, Chicago, IL, April 29-May 2, 2009. *Journal of the American Geriatrics Society* 2009; 57:S43-44.

Dublin S. Statin use and risk of pneumonia. Invited oral presentation, Young Investigators plenary session. 15th Annual HMO Research Network Conference, Danville, PA, April 29, 2009.

Moore KM, Cheetham TC, **Dublin S**, Hecht J, Robinson S, Brown JS. Virtual Data Warehouse pharmacy file: strengths, weaknesses, and recommendations (poster). 15th Annual HMO Research Network Conference, Danville, PA, April 2009.

Dublin S. Healthy user bias in studies of vaccine effects. Oral presentation as part of workshop titled, "Selective prescribing, frailty, and healthy-user effects in pharmacoepidemiology." 24th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Copenhagen, Denmark, August 19, 2008.

INVITED PRESENTATIONS

Birth Certificate Linkage: The Good, the Bad and the Unruly. Presentation to HMO Research Network Virtual Data Warehouse Improvement Group, Burlingame, CA, April 18, 2013.

Accounting for Bias in Medication Safety Studies that use Real-World Healthcare Data. Guest lecture to the Introduction to Pharmacoepidemiology class, University of North Carolina, Chapel Hill, NC, February 26, 2013.

Research Opportunities in Integrated Healthcare Delivery Systems. Invited seminar, University of North Carolina Department of Epidemiology, Chapel Hill, NC, February 26, 2013.

Accounting for Bias in Medication Safety Studies that use Real-World Healthcare Data. Invited seminar, Center for Pharmacoepidemiology Research and Training, University of Pennsylvania, January 31, 2013.

Statins and Infection: Miracle or Myth? Grand Rounds, University of Washington Division of Gerontology and Geriatric Medicine, January 18, 2013.

Accounting for Bias in Medication Safety Studies that Use Electronic Healthcare Data. Scientific seminar at Group Health Research Institute, December 11, 2012.

High-Risk Medications in the Elderly. Continuing Medical Education presentation to Group Health's Nursing Home Services division, Seattle, WA, June 7, 2012.

Studying Drug Safety in the Real World: New Data, Expanding Opportunities. Presentation to Medical Scientist Training Program (MD/PhD students), University of Washington, Seattle, WA, September 15, 2011.

Atrial Fibrillation: New Risk Factors and Outcomes. Continuing Medical Education presentation to Group Health's Nursing Home Services division, Seattle, WA, August 4, 2011.

NATIONAL RESPONSIBILITIES

Invited faculty, Society for Epidemiologic Research Student Workshop, Seattle, WA, June 2014
Member, Early Career Investigator Award selection committee, HMO Research Network Annual Meeting, January 2013
Member, Data Safety and Monitoring Board, randomized clinical trial: “Microbiology Testing With the Aim of Directed Antimicrobial Therapy for Community-Acquired Pneumonia,” Protocol 10-0061, National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases, 2012-July 2013. (Note: trial was never started.)
Abstract reviewer and session moderator, HMO Research Network Annual Meeting, 2012
Abstract reviewer, International Conference on Pharmacoepidemiology, yearly from 2009-present
Conference co-organizer, International Workshop on Pharmacoepidemiology and Biostatistics for visiting Chinese researchers and leaders in Traditional Chinese Medicine, Seattle, Washington, December 2-4, 2011
Planning Committee, Beeson Scholars Annual Meeting, 2011
Independent Safety Monitor for randomized clinical trials at Group Health, Vaccine Therapeutics Efficacy Unit, 2008-present.
Member, HMO Research Network Virtual Data Warehouse Pharmacy Working Group, 2008-2012

LOCAL RESPONSIBILITIES

Member, Faculty Search Committee, Group Health Research Institute, 2014
Founder and leader, Group Health Research Institute Pharmacoepidemiology and Therapeutics Methods Interest Group, 2009-present
Strategic Planning and Development Steering Committee, Group Health Research Institute, Seattle, WA, July 2011-January 2012
Clinician-Scientist Task Force, Group Health Research Institute, Seattle, WA, 2009
New Investigator Orientation Working Group, Group Health Research Institute, Seattle, WA, 2009
Diabetes Screening Guideline Development Group, Group Health, Seattle, WA, 2008

TEACHING

Masters Committees

Chair, Master’s thesis committee, Noa Kay, MPH in Epidemiology, University of Washington. “Adverse maternal and neonatal delivery outcomes associated with non-indicated labor induction at 39 weeks gestation.” Completed June 2011.

Member, Master’s thesis committee, Paul Jensen, MPH in Epidemiology, University of Washington. “Racial differences in the Incidence of and Risk Factors for Atrial Fibrillation in Older Adults: The Cardiovascular Health Study.” Completed December 2011.

Doctoral Committees

Member, Dissertation committee, Erin Wallace, PhD in Epidemiology, University of Washington. “Atrial Fibrillation and Disability-Free Survival, Functional Decline and the Risk of Hip and Forearm Fracture in the Cardiovascular Health Study.” Completed December 2013.

Other teaching and precepting

Small group preceptor, University of Washington School of Public Health and Community Medicine. EPI 514, Application of Epidemiologic Methods, Spring quarter of 2010, 2012, 2013 and 2014. Precepted small group of graduate students analyzing Washington State birth certificate and linked hospital discharge data.

Invited lecture, University of Washington School of Public Health and Community Medicine. EPI 533, Pharmacopidemiology. “Healthy user bias in observational studies of vaccine & medication effects: the limits of adjustment.” April 18, 2012.

Practicum supervisor, MPH practicum, Paul Jensen, 6/2010-2/2011, University of Washington. Project: systematic review for the Food and Drug Administration examining accuracy of algorithms using electronic health data to identify atrial fibrillation (for Mini-Sentinel.)

Invited lecture, University of Washington School of Public Health and Community Medicine. EPI 533, Pharmacopidemiology. “Healthy user bias in observational studies of vaccine & medication effects: the limits of adjustment.” May 10, 2010.

Invited session leader, University of Washington School of Public Health and Community Medicine. EPI 591A, Epidemiology Journal Club. “Acid-suppressing medications and risk of hospital-acquired pneumonia.” October 22, 2009.

University of Washington School of Medicine, Seattle, WA

2011	Problem-Based Learning (small group co-leader)	10 students, 16 contact hrs
2010	Problem-Based Learning (small group co-leader)	10 students, 16 contact hrs
2008	Problem-Based Learning (substitute group leader)	10 students, 6 contact hrs
2007	Problem-Based Learning (substitute group leader)	10 students, 10 contact hrs
2006	Problem-Based Learning (small group leader)	10 students, 30 contact hrs
2005	Problem-Based Learning (small group leader)	10 students, 30 contact hrs
2001	Introduction to Clinical Medicine	6 students; 6 contact hrs
	Taught physical exam skills to first-year medical students.	
1998 & 1999	Epidemiology (small group discussion leader)	10 students; 6 contact hrs
1998	Tutor, Epidemiology	3-50 students; ~12-15 hrs
	Led weekly reviews for first-year medical students & review sessions for USMLE I-II.	
1996-1998	T.A., Medicine, Health & Society	150 students; 30 hrs.; 3 yrs
	Participated in development of curriculum in health policy & economics for medical students; led small group discussion sessions.	
1994	T.A., Anatomy & Embryology	100 students; 70 contact hours

Oregon Health & Science University, Portland, OR

2002-03 Assisted with epidemiology course for physician assistant students; led journal clubs. Lectured to MPH students and Preventive Medicine students on pharmacoepidemiology and epidemiologic methods.

Kaplan Educational Centers, New York, NY and Seattle, WA

1996-1999 Seattle head MCAT instructor, training and supervising 6 other instructors
 1996 National MCAT organic chemistry coordinator
 1994-2000 Seattle MCAT instructor

PROFESSIONAL CERTIFICATION AND LICENSING

ABIM certification in Internal Medicine, 2004

Washington State medical license, 2001-present

CLINICAL RESPONSIBILITIES

Clinical practice: 1 day per week in primary care, Group Health Federal Way clinic.

OTHER PROFESSIONAL INVOLVEMENT

Peer reviewer, *Journal of General Internal Medicine*, 2005-present

- Named as distinguished reviewer in 2009

Ad hoc peer reviewer, *JAMA*, *Annals of Internal Medicine*, *BMJ*, *Archives of Internal Medicine*, *European Journal of Internal Medicine*, *Journal of Internal Medicine*, *Clinical Infectious Diseases*, and *Pharmacoepidemiology and Drug Safety*

- Named as a top reviewer (in top 10% by review quality) by *Annals of Internal Medicine* in 2008, 2009, 2010, 2011 and 2013 and as a distinguished reviewer by *Pharmacoepidemiology and Drug Safety* in 2010, 2011 and 2013

Associate council member, Society of General Internal Medicine Northwest Region, 2004-2007

- Developed and organized new session, Fellows' Work-in-Progress, highlighting work of Northwest region fellows and matching them with regional mentors

Lecturer on study skills and test-taking skills, Office of Multicultural Affairs, UW School of Medicine

- African American Mentorship Network Retreat, January 2005
- Pre-matriculation program, July 2005 and July 2006
- Pre-medical/pre-dental summer program, July 2005

Member, American Geriatrics Society, 2007-present

Member, American College of Physicians, July 2006–present

Member, International Society for Pharmacoepidemiology, 2007-present

Student member, Curriculum Committee, University of Washington School of Medicine, 1993-2001

COMMUNITY INVOLVEMENT

Interviewer, Brown Alumni Schools Committee, Portland, OR (2004) & Seattle, WA (2007, 2008, 2010)

Newborn Group leader, Program for Early Parent Support, Seattle, WA 2009-2010